Xenon Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 8c
November 3, 2016 4:57 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.51), $0.08 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $400 thousand versus the consensus estimate of $2.2 million.
Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, We have continued our momentum with a strong quarter, which included the completion of a successful... More
